Get startedLog in
    Picture of Monte Rosa Therapeutics logo

    GLUE — Monte Rosa Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapNeutral
    All News

    Brief: Monte Rosa Therapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Evaluating MRT-2359 For Treatment Of MYC-Driven Tumors

    Picture of Monte Rosa Therapeutics logoMonte Rosa Therapeutics
    01/11/2022 11:35
    Nov 1 (Reuters) - Monte Rosa Therapeutics Inc  GLUE.O :
    * MONTE ROSA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE
1/2 CLINICAL TRIAL EVALUATING MRT-2359, A GSPT1-DIRECTED
MOLECULAR GLUE DEGRADER, FOR TREATMENT OF MYC-DRIVEN TUMORS

Source text for Eikon:  ID:nGNX685sJT 
Further company coverage:  GLUE.O 
 ((Reuters.Briefs@thomsonreuters.com;;))

    Recent news on Monte Rosa Therapeutics

    See all news